ClinicalTrials.gg
RecruitingNCT07059299NeoTISLEGAUpdated Dec 19, 2025

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

A Phase 1 interventional study of Tislelizumab and FLOT Chemotherapy in Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Adenocarcinoma Of Esophagus with a site in Germany — 7 open to participants now, 15 under way, 5 of them phase 3. Adenocarcinoma Of Esophagus · Germany.

Planned enrollment
26th of 26
18 · median 230
Started
2025
the only one that year
Phase 1
4 of 29
1 open now
Primary completion
2027-08
later than 8 of 14 live
Registered
27th of 29
by date
Lead sponsor
2 of 29
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 29 studies in Adenocarcinoma Of Esophagus with a site in Germany, this one is the 26th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, reaches primary completion later than 8 of the 14 other live ones, and was the 27th registered.

Adenocarcinoma Of Esophagus

353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

7 of the 29 studies in Adenocarcinoma Of Esophagus with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Adenocarcinoma Of Esophagus with a site in Germany, or all of them as a file.
02

Study summary

With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA). The aim of this phase Ib trial is to determine whether this combination is safe and clinically active enough to support the continuation of this concept in subsequent trials investigating novel drug combinations in the neoadjuvant setting of locally advanced EGA. As many patients are unable to tolerate the postoperative part of the standard therapy concept, we aim here to assess a prolongation of preoperative therapy to 6 or 8 applications of FLOT, instead of the routinely administered 4 pre- and 4 postoperative applications, in combination with tislelizumab.

03

Conditions studied

  • Esophagogastric Junction Adenocarcinoma
  • Gastric Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Resectable Esophagogastric Adenocarcinoma
  • Neoadjuvant Therapy

Keywords

  • gastric cancer
  • FLOT
  • Tislelizumab
  • neoadjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient* has given written .
  2. Patient is ≥ 18 years of age at time of signing the written informed consent.
  3. Patient has proven locally advanced (cT2-4 , any cN , M0 OR any cT, cN+, M0 stage) gastric, esophageal or esophagogastric junction adenocarcinoma that:

    1. Is considered technically resectable.
    2. Does not involve distant site of the peritoneal cavity.

      • confirmed by diagnostic laparoscopy for all patients with tumors located in the stomach and those with type 2 and 3 GEJ adenocarcinomas according to ESMO guideline recommendation [Lordick et al. 2022].
      • Type 1 GEJ and esophageal adenocarcinomas can be enrolled without diagnostic laparoscopy (which is in line with guidelines and the current routine practice in Germany).
  4. Tumor material is available for local assessment of (CPS) and dMMR/MSI-status at the investigator´s site.
  5. Patient has an performance status 0 or 1.
  6. Patients has adequate blood count, liver-enzymes, and renal function:

    1. (Absolute neutrophil count) > 1,500 cells/μL without the use of hematopoietic growth factors.
    2. count ≥ 100 x 10\^9/L (>100,000 per mm3).
    3. ≥ 9 g/dL.
    4. Serum total ≤ 1.5x institutional upper normal limit ().
    5. (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN.
    6. Patients not receiving therapeutic anticoagulation must have an ≤ 1.5 ULN and aPTT ≤ 1.5 ULN. The use of full dose anticoagulants is allowed (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion.
    7. Serum Creatinine ≤ 1.5 x ULN and a calculated rate ≥ 50 mL /min.
  7. Female patients defined as women of (WOCBP) must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \< 1% per year during the treatment period and for 4 months after last dose of tislelizumab or 6 months after the last dose of chemotherapy, whatever is later. Male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use barrier contraceptives during the above period. Furthermore, male patients must refrain from donating sperm during this same period.

    • There are no data that indicate special gender distribution. Therefore, patients will be enrolled gender-independently in this trial.

Exclusion criteria

Exclusion Criteria:

  1. Patient received previous (radio)chemotherapy or immunotherapy for the same condition or within the past five years for any other cancerous condition.
  2. Patient received prior partial or complete esophagogastric resection.
  3. Patient has known to any component of the tislelizumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and/or any known (including hypersensitivity) to one of the study drugs.
  4. Patient has a history of (non-infectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease.
  5. Patient has lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within three months of the study randomization, severe asthma, severe , restrictive lung disease, pleural effusion etc.).
  6. Patient has inadequate cardiac function ( value \< 50 %) as determined by echocardiography.
  7. Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity.
  8. Patient received treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to study enrollment.
  9. Patients has pernicious anemia or other megaloblastic anemia due to vitamin B12 deficiency.
  10. Patient has peripheral sensitive neuropathy with functional deficits.
  11. Patient has a medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF; Class II to IV). Subjects with troponin levels above at screening (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during screening to rule out MI.
  12. Patient has a interval (QTc) prolongation to > 470 ms (females) or >450 ms (males) based on average of the screening triplicate12-lead .
  13. Participant has a known additional that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  14. Patient has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  15. Patient has active primary immunodeficiency, known uncontrolled active infection or active or C (HBV/) infection. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. Subjects with past or resolved HBV infection are eligible only if they meet all of the following criteria:

    • HBsAg(-) (for > 6 months off anti-viral treatment)
    • Anti-HBc(+) (IgG or total Ig)
    • HBV DNA undetectable
    • Absence of cirrhosis or fibrosis on prior imaging or
    • Absence of HCV co-infection or history of HCV co-infection
    • Access to a local hepatologist during and after the study
  16. Patient has active or history of disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
  17. Patient received treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within four weeks or five half-lives of the drug, whichever is longer, prior to study enrollment.
  18. Patient received treatment with systemic corticosteroids or other systemic medications within 2 weeks prior to study enrollment. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
  19. Patient received prior bone marrow transplantation or prior solid organ transplantation.
  20. Patient received live, attenuated vaccine within 30 days prior initiation of study drug.
  21. Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect.
  22. Patient participated in another interventional clinical study according to Medicines Act within 28 days prior to study enrollment or participation in a clinical study according to Medicines Act at the same time as this study unless it is an observational / non-interventional study or during the follow-up period of an interventional study.
  23. Patient has taken an drug within 28 days prior to initiation of study drug.
  24. Female patients, who are pregnant or breast feeding or planning to become pregnant within 7 months after the last dose of study treatment. Female patients of must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose intensification (Level 1 and 2)

    In the dose intensification part of the trial, eligible patients will be enrolled in a staggered approach with 6 patients for each successive dose level: Dose level 1 (n=6): * 4 cycles tislelizumab (200 mg, i.v. on day 1 Q3W ) plus * 6 cycles: FLOT (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU (5-fluorouracil) 2600 mg/m², all i.v. on day 1 Q2W) Dose level 2 (n=6): * 5 cycles tislelizumab (200 mg, i.v. on day 1 Q3W) plus * 8 cycles: FLOT (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W) The maximum dose level at which one or less out of 6 patients experienced a DLT is considered an optimal dose. In the expansion part of the trial, the dose level classified as optimal dose will be extended by a further 6 patients (12 patients in total for the optimal dose level).

    Drug: Tislelizumab · Drug: FLOT Chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Feasibility rate

    Feasibility rate, defined as proportion of patients receiving the protocol treatment before surgery ('neoadjuvant') according to the planned schedule without occurrence of at least one dose-limiting toxicity (DLT).

    Time frame: up to 8 months

07

Study locations

2 of 4 sites recruiting
  • Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)
    Frankfurt, 60488, Germany
    Recruiting
  • Hämatologisch-Onkologische Praxis Eppendorf (hope)
    Hamburg, 20249, Germany
    Not yet recruiting
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
    Not yet recruiting
  • Klinikum rechts der Isar München der TU München
    München, 81675, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jul 10, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07059299
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
BeiGene, Universitätsklinikum Leipzig
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Dec 12, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 19, 2025

Study contacts

Florian Lordick, Prof. Dr.
Contact
Florian.lordick@medizin.uni-leipzig.de
+49 341 97 12560
Claudia Pauligk, Dr.
Contact
neotislega@ikf-khnw.de
+49 (0) 69 / 5899 787 - 52
Florian Lordick, Prof. Dr.
principal investigator · Universitätsklinikum Leipzig
Salah Eddin Al-Batran, Prof. Dr.
study chair · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion